Conditions: Scleroderma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 47
Healthy volunteers: no

Brief summary:
The purpose of this study was to evaluate the safety of Dasatininb in the treatment of scleroderma pulmonary interstitial fibrosis.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: dasatinib
Intervention descriptions: intervention 1: Tablets, Oral, 100 mg, once daily, 6 months

Protocol document: